MAGEA3 and non-small cell lung carcinoma: This has been tested in the phase 2 trial NCT01159288, in which dendritic cell-derived exosomes loaded with multiple tumor-associated antigens (MAGE-3, MAGE-1, NY-ESO-1, MART-1) were expected to provoke a cytotoxic T-cell response against unresectable non-small cell lung cancer (NSCLC) [155,156].